Responses
Paediatrics
Protocol
Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial)
Compose a Response to This Article
Other responses
No responses have been published for this article.